Cryo-Cell International, Inc. (CCEL)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Cryo-Cell International, Inc. (CCEL) is down 1.5% since the beginning of the year. At $3 per share, CCEL is trading 46.6% below its 52-week high of $6. Investors who bought $1,000 worth of CCEL shares 5 years ago would now be looking at an investment worth $488.

Cryo-Cell International, Inc. (CCEL) has returned -1.45% so far this year and -32.83% over the past 12 months. Over the last ten years, CCEL has returned 3.15% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Feb 23, 2011, CCEL's average daily return is +0.08%, while the average monthly return is +1.11%. At this rate, an investment would double in approximately 5.2 years.

Historically, 44% of months were positive and 56% were negative. The best month was Apr 2023 with a return of +107.0%, while the worst month was Feb 2018 at -25.7%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 9 months.

On a daily basis, CCEL closed higher 34% of trading days. The best single day was Jul 1, 2015 with a return of +32.2%, while the worst single day was Mar 18, 2020 at -20.3%.

Cryo-Cell International, Inc. has an annualized alpha of 19.22%, beta of 0.13, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since February 24, 2011.

• This stock participated in 40.89% of S&P 500 Index downside but only 34.04% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.13 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CCEL ranks 17 for risk / return — in the bottom 17% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Cryo-Cell International, Inc. (CCEL) and compare them to S&P 500 Index.

Cryo-Cell International, Inc. provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.

The table displays the monthly dividend distributions for Cryo-Cell International, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Cryo-Cell International, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Cryo-Cell International, Inc. was 76.11%, occurring on Mar 28, 2023. The portfolio has not yet recovered.

The current Cryo-Cell International, Inc. drawdown is 70.15%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Cryo-Cell International, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Cryo-Cell International, Inc. is priced in the market compared to other companies in the Medical Care Facilities industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.